文献速递脑血管病

西酞普兰对急性缺血性卒中的神经再生与血管保护作用(TALOS研究)

Neuroregeneration and Vascular Protection by Citalopram in Acute Ischemic Stroke (TALOS).
PubMed 文献 · Stroke · 2018-01-01

TALOS研究是一项丹麦全国多中心、安慰剂对照、随机双盲研究,纳入642例非抑郁的首发缺血性卒中患者,在症状出现7天内启动西酞普兰治疗并随访6个月。结果显示,西酞普兰未改善1至6个月的功能恢复(OR 1.27,95%CI 0.92-1.74,P=0.057),心血管复合终点风险两组相似(HR 0.89,95%CI 0.50-1.60,P=0.24),药物耐受性良好。

要点

  • 早期西酞普兰治疗未显著改善非抑郁缺血性卒中患者6个月内的功能恢复(OR 1.27,95%CI 0.92-1.74,P=0.057)。
  • 西酞普兰组与安慰剂组的心血管复合终点风险相似(HR 0.89,95%CI 0.50-1.60,P=0.24)。
  • 西酞普兰治疗耐受性良好,研究期间共28例(4%)患者死亡(西酞普兰组16例 vs 安慰剂组12例,P=0.42)。

核心结论

  • 早期西酞普兰治疗未改善非抑郁缺血性卒中患者6个月内的功能恢复,尽管在分析人群中观察到临界统计学显著效应。
  • 治疗组间心血管事件风险相似,西酞普兰治疗耐受性良好。

研究设计与样本

  • TALOS研究是一项丹麦全国多中心、安慰剂对照、随机双盲研究,纳入非抑郁的首发缺血性卒中患者,在症状出现7天内启动西酞普兰治疗,作为标准医疗的附加治疗,治疗持续时间和随访为6个月。
  • 共纳入642例患者,随机分配至西酞普兰组(n=319)或安慰剂组(n=323)。
  • 有两个共同主要终点:1至6个月改良Rankin量表功能残疾变化,以及前6个月内短暂性脑缺血发作/卒中、心肌梗死或血管性死亡的复合血管终点。

主要发现

  • 入院时美国国立卫生研究院卒中量表评分中位数西酞普兰组为5.3(范围0-27),安慰剂组为4.8(范围0-28)。
  • 1至6个月功能恢复改善在西酞普兰组有160例(50%),安慰剂组有136例(42%)(OR 1.27,95%CI 0.92-1.74,P=0.057);排除31天前脱落者(n=90)后,分析人群OR为1.37(95%CI 0.97-1.91,P=0.07)。
  • 在中位随访150天期间,西酞普兰组23例(7%)和安慰剂组26例(8%)患者发生主要血管终点(HR 0.89,95%CI 0.50-1.60,P=0.24)。
  • 研究期间共28例患者(4%)死亡(西酞普兰组16例 vs 安慰剂组12例,P=0.42)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background and Purpose- Recent studies indicate a possible beneficial effect on neuroregeneration and vascular protection of selective serotonin reuptake inhibitors after stroke. We conducted a national multicentre study to explore these effects. Methods- The TALOS study (The Efficacy of Citalopram Treatment in Acute Stroke) is a Danish placebo-controlled, randomized, double-blind study of citalopram started within 7 days after symptom onset to detect improvement in functional outcomes and cardiovascular protection in nondepressed, first-ever ischemic stroke. Study medication was given as add-on to standard medical care and treatment duration and follow-up was 6 months. There were 2 coprimary outcomes: changes in functional disability from 1 to 6 months on the modified Rankin Scale, and a composite vascular end point of transient ischemic attack/stroke, myocardial infarction, or vascular mortality during the first 6 months. Results- We enrolled 642 patients randomized to either citalopram (n=319) or placebo (n=323). Median National Institutes of Health Stroke Scale was 5.3 (range, 0-27) versus 4.8 (range, 0-28) at admission. Improvement in functional recovery from 1 to 6 months occurred in 160 (50%) patients on citalopram and 136 (42%) on placebo (odds ratio, 1.27; 95% CI, 0.92-1.74; P=0.057). When dropouts before 31 days were excluded (n=90), the analysis population showed an odds ratio of 1.37 (95% CI, 0.97-1.91; P=0.07). During a median follow-up of 150 days, 23 (7%) patients in the citalopram group and 26 (8%) patients in the placebo group had a primary, vascular end point (hazard ratio, 0.89; 95% CI, 0.50-1.60; P=0.24). A total of 28 patients (4%) died (16 versus 12; P=0.42) during the study. Conclusions- Early citalopram treatment did not improve functional recovery in nondepressed ischemic stroke patients within the first 6 months, although a borderline statistical significant effect was observed in the analysis population. The risk of cardiovascular events was similar between treatment groups, and citalopram treatment was well tolerated. Clinical Trial Registration- URL: https://www.clinicaltrials.gov . Unique identifier: NCT01937182. URL: https://www.clinicaltrialsregister.eu/ . EudraCT number: 2013-002253-30.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Kraglund KL, Mortensen JK, Damsbo AG, et al. Neuroregeneration and Vascular Protection by Citalopram in Acute Ischemic Stroke (TALOS). Stroke. 2018. PMID: 30355209. doi:10.1161/STROKEAHA.117.020067

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。